Active targeting of mesoporous silica drug carriers enhances γ-secretase inhibitor efficacy in an in vivo model for breast cancer.

AIM In this article, we use an alternative cancer model for the evaluation of nanotherapy, and assess the impact of surface functionalization and active targeting of mesoporous silica nanoparticles (MSNPs) on therapeutic efficacy in vivo. MATERIALS & METHODS We used the chorioallantoic membrane xenograft assay to investigate the biodistribution and therapeutic efficacy of folate versus polyethyleneimine-functionalized γ-secretase inhibitor-loaded MSNPs in breast and prostate tumor models. RESULTS γ-secretase inhibitor-loaded MSNPs inhibited tumor growth in breast and prostate cancer xenografts. Folate conjugation improved the therapeutic outcome in folic acid receptor-positive breast cancer, but not in prostate cancer lacking the receptor. CONCLUSION The results demonstrate that therapeutic efficacy is linked to cellular uptake of MSNPs as opposed to tumor accumulation, and show that MSNP-based delivery of γ-secretase inhibitors is therapeutically effective in both breast and prostate cancer. In this article, we present a model system for a medium-to-high throughput, cost-effective, quantitative evaluation of nanoparticulate drug carriers.

[1]  Y. Maitani,et al.  Folate-linked nanoparticle-mediated suicide gene therapy in human prostate cancer and nasopharyngeal cancer with herpes simplex virus thymidine kinase , 2005, Cancer Gene Therapy.

[2]  J. Rosenholm,et al.  Amino-functionalization of large-pore mesoscopically ordered silica by a one-step hyperbranching polymerization of a surface-grown polyethyleneimine. , 2006, Chemical communications.

[3]  M. Bissell,et al.  Of extracellular matrix, scaffolds, and signaling: tissue architecture regulates development, homeostasis, and cancer. , 2006, Annual review of cell and developmental biology.

[4]  J. Eriksson,et al.  Targeted intracellular delivery of hydrophobic agents using mesoporous hybrid silica nanoparticles as carrier systems. , 2009, Nano letters.

[5]  Juergen Friedrich,et al.  Experimental anti-tumor therapy in 3-D: Spheroids – old hat or new challenge? , 2007, International journal of radiation biology.

[6]  Ze Lu,et al.  Improving delivery and efficacy of nanomedicines in solid tumors: role of tumor priming. , 2011, Nanomedicine.

[7]  James P. Quigley,et al.  Chick embryo chorioallantoic membrane model systems to study and visualize human tumor cell metastasis , 2008, Histochemistry and Cell Biology.

[8]  U. Bhanot,et al.  Small molecule XIAP inhibitors enhance TRAIL-induced apoptosis and antitumor activity in preclinical models of pancreatic carcinoma. , 2009, Cancer research.

[9]  M. Katsogiannou,et al.  Active-targeted nanotherapy strategies for prostate cancer. , 2011, Current cancer drug targets.

[10]  E. Ruoslahti,et al.  Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. , 1998, Science.

[11]  Jessica M. Rosenholm and,et al.  Wet-Chemical Analysis of Surface Concentration of Accessible Groups on Different Amino-Functionalized Mesoporous SBA-15 Silicas , 2007 .

[12]  L. Sillerud,et al.  Prostate cancer targeting motifs: Expression of ανβ3, neurotensin receptor 1, prostate specific membrane antigen, and prostate stem cell antigen in human prostate cancer cell lines and xenografts , 2012, The Prostate.

[13]  William C Hines,et al.  Why don't we get more cancer? A proposed role of the microenvironment in restraining cancer progression , 2011, Nature Medicine.

[14]  Chindo Hicks,et al.  Cross-talk between notch and the estrogen receptor in breast cancer suggests novel therapeutic approaches. , 2008, Cancer research.

[15]  J. Eriksson,et al.  Cancer-cell-specific induction of apoptosis using mesoporous silica nanoparticles as drug-delivery vectors. , 2010, Small.

[16]  Rasmus Niemi,et al.  Targeting of porous hybrid silica nanoparticles to cancer cells. , 2009, ACS nano.

[17]  Cecilia Sahlgren,et al.  Mesoporous silica nanoparticles as drug delivery systems for targeted inhibition of Notch signaling in cancer. , 2011, Molecular therapy : the journal of the American Society of Gene Therapy.

[18]  Minhong Yan,et al.  Chronic DLL4 blockade induces vascular neoplasms , 2010, Nature.

[19]  Benjamin Purow,et al.  Notch inhibition as a promising new approach to cancer therapy. , 2012, Advances in experimental medicine and biology.

[20]  C. M. Roth,et al.  Nanoscale drug delivery systems for enhanced drug penetration into solid tumors: current progress and opportunities. , 2012, Critical reviews in biomedical engineering.

[21]  Laurence Raehm,et al.  Cancer therapy improvement with mesoporous silica nanoparticles combining targeting, drug delivery and PDT. , 2012, International journal of pharmaceutics.

[22]  M. Maynadier,et al.  Multifunctionalized mesoporous silica nanoparticles for the in vitro treatment of retinoblastoma: Drug delivery, one and two-photon photodynamic therapy. , 2012, International journal of pharmaceutics.

[23]  D. Ribatti,et al.  In vivo inhibition of human hepatocellular carcinoma related angiogenesis by vinblastine and rapamycin. , 2007, Histology and histopathology.

[24]  Daniel A. Heller,et al.  Treating metastatic cancer with nanotechnology , 2011, Nature Reviews Cancer.

[25]  S. Morrison,et al.  Targeting, Imaging, and Therapy Using a Humanized Antiprostate Stem Cell Antigen (PSCA) Antibody , 2007, Journal of immunotherapy.

[26]  U. Lendahl,et al.  Notch signaling mediates hypoxia-induced tumor cell migration and invasion , 2008, Proceedings of the National Academy of Sciences.

[27]  Jay S. Fine,et al.  Chronic Treatment with the γ-Secretase Inhibitor LY-411,575 Inhibits β-Amyloid Peptide Production and Alters Lymphopoiesis and Intestinal Cell Differentiation* , 2004, Journal of Biological Chemistry.

[28]  S. Christensen,et al.  Engineering a Prostate-Specific Membrane Antigen–Activated Tumor Endothelial Cell Prodrug for Cancer Therapy , 2012, Science Translational Medicine.

[29]  Pauliina Kronqvist,et al.  Hypo- and hyperactivated Notch signaling induce a glycolytic switch through distinct mechanisms , 2011, Proceedings of the National Academy of Sciences.

[30]  A. Harris,et al.  Targeting DLL4 in tumors shows preclinical activity but potentially significant toxicity. , 2010, Future oncology.

[31]  J. Karp,et al.  Nanocarriers as an Emerging Platform for Cancer Therapy , 2022 .

[32]  V. Adhami,et al.  Targeted Knockdown of Notch1 Inhibits Invasion of Human Prostate Cancer Cells Concomitant with Inhibition of Matrix Metalloproteinase-9 and Urokinase Plasminogen Activator , 2009, Clinical Cancer Research.

[33]  Gert Storm,et al.  Sheddable Coatings for Long-Circulating Nanoparticles , 2007, Pharmaceutical Research.

[34]  Neetu Singh,et al.  Nanoparticles that communicate in vivo to amplify tumour targeting. , 2011, Nature materials.

[35]  M. Maynadier,et al.  Mannose-functionalized mesoporous silica nanoparticles for efficient two-photon photodynamic therapy of solid tumors. , 2011, Angewandte Chemie.

[36]  Cecilia Sahlgren,et al.  Nanoparticles in targeted cancer therapy: mesoporous silica nanoparticles entering preclinical development stage. , 2012, Nanomedicine.

[37]  R. Hautmann,et al.  Chorioallantoic membrane assay: vascularized 3-dimensional cell culture system for human prostate cancer cells as an animal substitute model. , 2001, The Journal of urology.

[38]  Meena Mahmood,et al.  Engineered nanostructural materials for application in cancer biology and medicine , 2012, Journal of applied toxicology : JAT.

[39]  S. Rayala,et al.  Nanomedicine: towards development of patient-friendly drug-delivery systems for oncological applications , 2012, International journal of nanomedicine.

[40]  S. Vinogradov,et al.  Cancer stem cells and drug resistance: the potential of nanomedicine. , 2012, Nanomedicine.

[41]  H. Schneckenburger,et al.  Light exposure and cell viability in fluorescence microscopy , 2012, Journal of microscopy.

[42]  Robert Langer,et al.  Nanoparticle delivery of cancer drugs. , 2012, Annual review of medicine.

[43]  Mina J Bissell,et al.  Context, tissue plasticity, and cancer: are tumor stem cells also regulated by the microenvironment? , 2005, Cancer cell.

[44]  Cecilia Sahlgren,et al.  Mesoporous silica nanoparticles in medicine--recent advances. , 2013, Advanced drug delivery reviews.

[45]  Ralph Weissleder,et al.  Detection of early prostate cancer using a hepsin-targeted imaging agent. , 2008, Cancer research.

[46]  R. Clarke,et al.  Aberrant Activation of Notch Signaling in Human Breast Cancer , 2006 .

[47]  R. Gurny,et al.  Screening of nanoparticulate delivery systems for the photodetection of cancer in a simple and cost-effective model. , 2009, Nanomedicine.

[48]  Robert Gurny,et al.  The chick embryo and its chorioallantoic membrane (CAM) for the in vivo evaluation of drug delivery systems. , 2007, Advanced drug delivery reviews.

[49]  R. Hibst,et al.  Matrix-dependent regulation of AKT in Hepsin-overexpressing PC3 prostate cancer cells. , 2011, Neoplasia.

[50]  S. Fulda,et al.  Targeting XIAP bypasses Bcl-2-mediated resistance to TRAIL and cooperates with TRAIL to suppress pancreatic cancer growth in vitro and in vivo. , 2008, Cancer research.

[51]  Jayanta Debnath,et al.  Modeling morphogenesis and oncogenesis in three-dimensional breast epithelial cultures. , 2008, Annual review of pathology.

[52]  Erkki Ruoslahti,et al.  Targeting of drugs and nanoparticles to tumors , 2010, The Journal of cell biology.

[53]  Paul Leonard,et al.  Nanomedicine: barcodes check out prostate cancer. , 2010, Nature nanotechnology.

[54]  Thomas Efferth,et al.  Therapeutic and diagnostic applications of nanoparticles. , 2011, Current drug targets.

[55]  Hans Clevers,et al.  Notch/γ-secretase inhibition turns proliferative cells in intestinal crypts and adenomas into goblet cells , 2005, Nature.